Please Wait
Applying Filters...
menu
    • menu
    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Silmitasertib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 455,125Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Senhwa Biosciences Reports Positive Data from Silmitasertib Trial
    Senhwa Biosciences Reports Positive Data from Silmitasertib Trial

    02 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-positive-clinical-data-from-phase-1expansion-trial-of-silmitasertib-cx-4945-in-the-treatment-of-basal-cell-carcinoma-302418218.html

    PR NEWSWIRE
    02 Apr 2025
    Share Share
    Senhwa Announces First Patient Dosed in the Phase II of Silmitasertib
    Senhwa Announces First Patient Dosed in the Phase II of Silmitasertib

    20 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-ii--study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-associated-with-viral-infection-in-taiwan-302094217.html

    PR NEWSWIRE
    20 Mar 2024
    Share Share
    Senhwa Bio Received US FDA IND Approval for Phase II Study of Silmitasertib
    Senhwa Bio Received US FDA IND Approval for Phase II Study of Silmitasertib

    21 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-received-us-fda-ind-approval-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301994554.html

    PR NEWSWIRE
    21 Nov 2023
    Share Share
    Senhwa Announces First Patient Dosed in Taiwan Phase II Study of Silmitasertib
    Senhwa Announces First Patient Dosed in Taiwan Phase II Study of Silmitasertib

    09 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-first-patient-successfully-dosed-in-taiwan-phase-ii-study-of-silmitasertib-in-hospitalized-adults-with-covid-19-301982962.html

    PR NEWSWIRE
    09 Nov 2023
    Share Share
    Senhwa Announces IND Submission to US FDA for Phase II Study of Silmitasertib
    Senhwa Announces IND Submission to US FDA for Phase II Study of Silmitasertib

    19 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-ind-submission-to-us-fda-for-phase-ii-study-of-silmitasertib-in-patients-with-community-acquired-pneumonia-cap-associated-with-viral-infection-301961780.html

    PR NEWSWIRE
    19 Oct 2023
    Share Share
    Taiwan FDA approves Senhwa Biosciences’ ph II IND application of Silmitasertib
    Taiwan FDA approves Senhwa Biosciences’ ph II IND application of Silmitasertib

    02 May 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=157818&sid=2

    PHARMABIZ
    02 May 2023
    Share Share